The company remains in a pre-revenue phase, reporting $0 in revenue while incurring $284.5 thousand in SG&A expenses during 2026Q1.
| Sales/Revenue | 0 | - | - |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | - | - |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 284.48K | 559.97K | 166 |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 284.48K | 559.97K | 166 |
| SG&A % of Revenue | - | - | - |
| Research & Development | 0 | - | - |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | - | - |
| Operating Income | -284.48K | -559.97K | -165 |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -339278.18% | - |
| EBITDA | -284.48K | -559.97K | 1 |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -77774266.67% | - |
| D&A (Non-Cash Add-back) | 5 | 0 | 166 |
| EBIT | -284.48K | -559.97K | -165 |
| Net Interest Income | 2.27M | 5.33M | 0 |
| Interest Income | 2.27M | 5.33M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 0 | - | - |
| Pretax Income | 1.99M | 4.78M | -165 |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% |
| Net Income | 1.99M | 4.78M | -165 |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 2898451.52% | - |
| Net Income (Continuing) | 1.99M | 4.78M | -165 |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | - | 0.24 | -0.03 |
| EPS Growth % | - | 897.34% | - |
| EPS (Basic) | - | 0.25 | -0.03 |
| Diluted Shares Outstanding | 25.3M | 13.52M | 5.5K |
| Basic Shares Outstanding | 25.3M | 13.52M | 5.5K |
| Dividend Payout Ratio | - | - | - |
Execution and redemption risk
As reported in recent financial filings, PACH incurred $284.5K in SG&A expenses during 2026Q1, reflecting the necessary administrative and professional costs required to identify a suitable merger target while maintaining its public listing status without generating any operational revenue to offset these ongoing cash outflows.
The company's cost structure is currently dominated by search-related expenditures, which are essential for the de-SPAC process but inherently non-productive in the absence of a target. Investors should monitor the efficiency of these outlays, as the limited cash reserves of $764,902 suggest that management faces mounting pressure to secure a transaction before requiring additional sponsor-funded capital injections.
Based on the company's 2026Q1 income statement, the reported $2.0M net income appears to be a non-cash artifact rather than operational success, likely driven by fluctuations in the fair value of warrant liabilities rather than any underlying improvement in the firm's core business or revenue-generating capabilities.
Analysts should exercise caution when interpreting the bottom-line figure, as it masks the underlying cash burn associated with the search for a business combination. This accounting treatment warrants further investigation, as it does not reflect the economic reality of a pre-revenue entity that remains entirely dependent on its trust account for long-term viability.
According to the latest quarterly data, the company's cash position of $764,902 relative to its quarterly SG&A burn rate suggests a narrow window for target identification, which may force management into suboptimal deal-making decisions if the search process extends beyond the current projected timeline for capital exhaustion.
The reliance on sponsor-funded expenses to sustain operations creates a potential conflict of interest that investors should monitor closely. If the search for a healthcare-focused target proves more protracted than anticipated, the resulting dilution from necessary bridge financing could significantly impair the value proposition for public shareholders.
Quick answers to the most common questions about buying PACH stock.
Pioneer Acquisition I Corp. (PACH) is profitable, generating $4.8M in net income for the fiscal year ending 2025.